Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Share-based Compensation (2023 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Share-based Compensation for 3 consecutive years, with $34882.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 94.79% to $34882.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $3.8 million, a 40.17% increase, with the full-year FY2024 number at $3.6 million, up 582.26% from a year prior.
  • Share-based Compensation was $34882.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from $34503.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.6 million in Q4 2024 to a low of -$832118.0 in Q4 2023.
  • A 3-year average of $735904.5 and a median of $212605.0 in 2023 define the central range for Share-based Compensation.
  • Biggest YoY gain for Share-based Compensation was 1602.61% in 2025; the steepest drop was 98.8% in 2025.
  • 60 Degrees Pharmaceuticals' Share-based Compensation stood at -$832118.0 in 2023, then surged by 531.84% to $3.6 million in 2024, then crashed by 99.03% to $34882.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Share-based Compensation are $34882.0 (Q3 2025), $34503.0 (Q2 2025), and $142645.0 (Q1 2025).